FORM 7

August 2020 - MONTHLY PROGRESS REPORT

Name of Listed Issuer:	**Valeo Pharma Inc. (the "Issuer" or the "Company")**
Trading Symbol:	**VPH**
Number of Outstanding Listed Securities:	**58 238 859**
Date:	**September 4th, 2020**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   The Issuer continued to implement various strategic and operational initiatives, namely:

   1) Maximize the commercial potential of its products currently on the market

   2) Prepare for the launch of Health Canada approved products not yet commercialized.

3) **Execute any required regulatory, quality, supply chain, operational, marketing, and commercial activities required to support the above 2 initiatives as well as for products still in the process of obtaining regulatory approval.**

4) **Actively promote itself to/and negotiate with local and foreign companies for securing Canadian rights to additional products that would represent a great complement to its existing product portfolio.**

5) **Actively promote itself to potential institutional, and retail investors including life science analysts covering the Canadian healthcare sector.**

6) **Complete and file an application to list the Company's Class A shares on the OTCQB market in the United States. The listing of the Company's Shares on the OTCQB remains subject to the Company fulfilling all the listing requirements of the OTCQB and any other regulatory requirements. The Company will continue to maintain the listing of its Shares on the CSE under the symbol "VPH". The Company's shares were listed on the Frankfurt Stock Exchange (FSE) under the symbol VP2.**

7) **Prepare a dedicated transactional website in anticipation of the commercial launch of its bioflavonoid formulation, Hesperco™, in Canada.**

2. Provide a general overview and discussion of the activities of management.

   Support activities listed in section 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   The Company commenced commercializing Yondelis® in Canada following the receipt of a Notice of Compliance from Health Canada authorizing the transfer of the commercial rights of Yondelis® to Valeo. Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain.

   The Company also filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, Hesperco™. Hesperco™ capsules contain a powerful antioxidant that can be taken for immune system support.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   Nothing applicable during the period.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   VPI Pharmaceuticals Inc., a wholly owned subsidiary of the Company focused on the commercialization of hospital products, entered into a licensing agreement with

Leading Pharma, LLC, for the distribution and commercialization of Ethacrynate Sodium in the United States of America.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Nothing applicable during the period.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Nothing applicable during the period.

8. Describe the acquisition of new customers or loss of customers.

Nothing applicable during the period.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

Nothing applicable during the period

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

Nothing applicable during the period.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Nothing applicable during the period.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Nothing applicable during the period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Nothing applicable during the period

14. Provide details of any securities issued and options or warrants granted.

The Company entered into an agreement with a syndicate of underwriters led by Stifel GMP (the "Lead Underwriter", and collectively with the syndicate of underwriters, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase from the Company, on a bought deal basis pursuant to the filing of a short form prospectus, 5,000,000 units of the Company (the "Units") at a price of $1.20 per Unit (the "Offering Price") for gross proceeds of $6.0 million (the "Offering"). Each Unit shall consist of one common share of the Company and one-half common share purchase warrant (each whole warrant, a "Unit Warrant"), with each Unit Warrant entitling the holder to purchase one common share of the Company at a price of $1.50 until 24 months after the closing of the Offering and

will be subject to an accelerated expiration if the closing price of the Company's common shares on the Canadian Securities Exchange (the "CSE") is equal to or greater than $2.00 for a period of ten consecutive trading days.

The Company also announced that it has no intention at this time to accelerate the expiry of the share purchase warrants of the Company issued pursuant to a short form prospectus dated July 11, 2019, each Warrant having an exercise price of $0.60 and an expiry date of July 25, 2022. All other terms of these Warrants remain unchanged, including the right of the Company to accelerate on occurrence of a subsequent acceleration event in accordance with the terms of the Warrants.

Exercise of Warrants and Compensation Options

In August 2020, the Company issued 130,350 Class "A" shares, for net proceeds of $78,210 following the exercise of an equivalent number of listed warrants expiring July 25, 2022 ("Listed Warrants"). During the month of August, no compensation options ("Compensation Options") were exercised by brokers.

Since the beginning of the fiscal year, 447,550 Listed Warrants and 23,320 Compensation Options were exercised, bringing in net proceeds to the Company of $268,530 and $11,660, respectively.

Convertible Debentures

In August 2020, no Convertible Debentures, Series 1 ("Convertible Debentures") were converted.

Since the beginning of the fiscal year, the Company issued 1,058,570 Class "A" Shares following the conversion of Convertible Debentures for an aggregate of $423,428 in principal and interest.

15. Provide details of any loans to or by Related Persons.

Nothing applicable during the period.

16. Provide details of any changes in directors, officers or committee members.

Nothing applicable during the period.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The outbreak of a novel strain of the coronavirus, ("COVID-19"), has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures have caused material disruption to businesses globally resulting in an economic slowdown which may impact demand for our products and our ability to secure timely access to supplies. As of today, our revenues and supply chain have not been impacted by the COVID-19 outbreak and we continue to interact with the medical community while respecting social-distancing recommendations.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: September 4th, 2020

Valeo Pharma Inc.
/s/ Luc Mainville
Senior VP & Chief Financial Officer
Official Capacity

Issuer Details Name of Issuer Valeo Pharma Inc.	For Month End August 2020	Date of Report YY/MM/D 2020/09/04
Issuer Address 16667, Boul. Hymus,		
City/Province/Postal Code Kirkland, Quebec, H9H 4R9	Issuer Fax No. (514) 694-0865	Issuer Telephone No. (514) 694-0150
Contact Name Luc Mainville	Contact Position Sr. VP & CFO	Contact Telephone No. (514) 693-8854
Contact Email Address mainville@valeopharma.com	Web Site Address www.valeopharma.com	